Adenovirus Covid-19 vaccine shows lower but ‘stable’ immunity level for 8 months while mRNA jabs’ efficacy falls ‘sharply’ – study

Different effects of the world’s Covid injection types are revealed in new study that shines light on ‘Adenovirus v mRNA’ debate

The one-shot adenovirus J&J Covid-19 vaccine provides stable but low-level immunity that stays for months, a new study has found, while mRNA jabs’ initially higher number of antibodies “declines sharply”During the same time period.

An immune response induced by Johnson & Johnson’s Janssen adenovirus vaccine appears to show “minimal-to-no evidence of decline”The US has released a new study that outlines the dynamic of the immune response over the past eight months. It is the result of a fresh research. “follow-up period”Following immunizations for each of the American vaccines.

Learn more

FDA panel gives nod to Johnson & Johnson booster Covid-19 jabs

Apparently, Pfizer and Moderna cannot boast a similar durability in their mRNA vaccines’ efficacy, the study shows. Both of their antibody titer (a measurement term) tends to decrease. “sharply by six months after vaccination”The data from specialists at the Beth Israel Deaconess Medical Center (Boston, Massachusetts) and University of North Carolina Chapel Hill show that the number of people who have experienced a fall in their health has increased by 8 months.

The two mRNA vaccines apparently still greatly outperform the one-shot Johnson & Johnson jab during the “peak immunity”The study admits that this period is between 2 and 4 weeks following full immunization. In the long run, however, they quickly lose their sizeable lead in efficacy and eventually land at the same antibody response level as that of the Johnson & Johnson jab based on the adenovirus vector principle – the same as the ones used by the UK’s AstraZeneca and by Russia’s Sputnik V.

The study also demonstrated that the Johnson & Johnson jab supposedly even somewhat outperforms both mRNA vaccines when it comes to antibody responses eight months after full immunization. The live-virus neutralizing antibody reaction and certain types of T-cell responses were higher than the Moderna and Pfizer jabs.

‘Statistical discrepancy’ or potential breakthrough?

Whether it is indeed better in the long run is difficult to ascertain, though, since the data obtained from just over 60 participants, including only eight immunized with a Johnson & Johnson jab, appear to be somewhat “lacking,”Maxim Skulachev is a prominent research associate at Belozersky Institute, Moscow State University (MSU).

“There are not enough statistics,”When asked about the results of his study, he replied to RT. In fact, Janssen jab’s better performance could be a matter of “statistical discrepancy,”He said that he was happy to add. He also pointed to the fact that the study did not include the new data on Johnson & Johnson booster shot. also available
EMA approves Pfizer BioNTech Manufacturing Sites and Covid Vaccine Formula as It Considers Extending Jabs for Children 5-11

The study came just about a week after Russia published results of a study that its own one-shot adenoviral vector vaccine – Sputnik Light – offers at least 70% protection against the Covid-19 Delta variant for at least three months after vaccination. Moreover, the director of the Gamaleya National Research Center of Epidemiology and Microbiology, which developed Russia’s leading vaccine, Alexander Gintsburg, claimed that getting a booster shot of Sputnik Light, after initial vaccination with Sputnik V, prolongs immunity by six to seven months.

“Additional boosting with the second component of Sputnik V raises the level of protective antibodies and is quite significant. Sputnik Light alone is sufficient to boost the bounding antibodies units (BAU) in the 300-500 range. And, accordingly, this is the most common range after six months of using Sputnik V, so the use of Sputnik Light after six months for such a category of vaccinated people is a very promising and effective way to extend protective immunity for at least another six to seven months,”He cited data from over 4,000 Moscow residents who were vaccinated, and he stated that.

It is possible that the Russian jab could also be successful used as a weapon. “booster shot” to re-vaccinate people who’ve earlier been immunized with other vaccines. A small-scale study in Azerbaijan this year showed in particular a fourfold increase in antibodies to the spike protein of the virus in 85% of participants in a Sputnik Light clinical trial, who’d previously been immunized with AstraZeneca’s jab.

Learn more

Second dose of J&J Covid jab increases protection to 94%, firm’s data shows

Skulachev is also optimistic that Sputnik Light may prove to be an acceptable re-vaccination method. He said that the study of three American vaccines revealed similar effectiveness over time. One of them is an adenoviral vector 1. “we can assume it will work with Sputnik as well.”

In September, the Johnson & Johnson pharmaceutical company said that administering the booster dose some two months after the first dose made antibody levels four to six times higher and raised the vaccine’s efficacy to 94% against moderate and severe Covid-19 cases – up from just 66% provided by the first dose.

Last week, the US Food and Drug Administration (FDA) endorsed J&J’s booster proposal, even though it did not set a fixed timeline for administering the second shot.

Skulachev stated that the results of the current study might still be positive news for vector vaccines adenoviral. Although the antibody response level provided by the one-shot Johnson & Johnson jab is “more than 10 times lower”The mRNA vaccines were more effective than those given during the “peak immunity period,”He believes its endurance is a credit to it.

“It is clear that it is definitely not worse in the long run,”Skulachev added that Skulachev believed the “greatest result”This study has shown that every vaccine provides some protection. “baseline”Immunity can persist for up to eight months even after vaccination. also available
One-shot Sputnik Light shows 70% efficacy against Covid-19 Delta variant & strong potency as booster for other vaccines – study

“Over time, immunity responses induced by all vaccines come to a certain ‘steady state,’ which protects from hospitalization and death,”Skulachev explained, but added that this might not be sufficient to prevent a person contracting the disease.

“We have this baseline immunity induced by all vaccines. It protects. [a person] against hospitalization,”He added that such data should be called “data” “reassuring.” This ‘baseline’ immunity could also be a good basis for re-vaccination booster shots, the scientist believes.

Are you sure your friends would find this interesting? Tell your friends!



Related Articles

Back to top button